We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice. In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry.  Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Acc ..read more

In this episode, we're dissecting the US Administrations initiative to overhaul Medicare Part B drug reimbursement, incorporating international reference pricing. Experts on call Ulrich Neumann, Sr. Director, US Access ulrich.neumann@certara.com Additional notes: - We referenced the Implications of Pricing on Innovation which is thoroughly discussed in this article by USC's Darius Lakdawalla Lakdawalla, Darius N. 2018. "Economics of the Pharmaceutical Industry." Journal of Economic Literature, 56 (2): 397-449. DOI: 10.1257/jel.20161327 --- Send in a voice message: https://podcasters.spotify.co ..read more

Listen in for this stakeholder panel on strategic collaborations with hospital & provider systems, IDNs and ACOs to bring value-based care to patients. Experts on call Shontelle Dodson, SVP, Astellas Matt Portch, VP Sunovion, Gergana Zlateva, VP Pfizer, Terrill Jordan, CEO of the RCCA provider network Ulrich Neumann, Sr. Director, Head US Access, Certara (ulrich.neumann@certara.com) --- Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message ..read more

In our first episode, we're shining a light on the next frontier for outcomes-based agreements (OBA). If we move beyond the initial excitement and PR, where does pharma stand on risk-sharing and innovative contracting? Experts Roman Casciano, GM, Analytica Laser & SVP, Market Access, HEOR and Real-world Evidence, Certara Lee Stern, VP, Business Development, Certara Evidence & Access Ulrich Neumann, Sr. Director, Head US Access, Certara (ulrich.neumann@certara.com) --- Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message ..read more

We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice. In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry.  Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Acc ..read more

In this episode, we're dissecting the US Administrations initiative to overhaul Medicare Part B drug reimbursement, incorporating international reference pricing. Experts on call Ulrich Neumann, Sr. Director, US Access ulrich.neumann@certara.com Additional notes: - We referenced the Implications of Pricing on Innovation which is thoroughly discussed in this article by USC's Darius Lakdawalla Lakdawalla, Darius N. 2018. "Economics of the Pharmaceutical Industry." Journal of Economic Literature, 56 (2): 397-449. DOI: 10.1257/jel.20161327 --- Send in a voice message: https://anchor.fm/market-acce ..read more

Listen in for this stakeholder panel on strategic collaborations with hospital & provider systems, IDNs and ACOs to bring value-based care to patients. Experts on call Shontelle Dodson, SVP, Astellas Matt Portch, VP Sunovion, Gergana Zlateva, VP Pfizer, Terrill Jordan, CEO of the RCCA provider network Ulrich Neumann, Sr. Director, Head US Access, Certara (ulrich.neumann@certara.com) --- Send in a voice message: https://anchor.fm/market-access/message ..read more

In our first episode, we're shining a light on the next frontier for outcomes-based agreements (OBA). If we move beyond the initial excitement and PR, where does pharma stand on risk-sharing and innovative contracting? Experts Roman Casciano, GM, Analytica Laser & SVP, Market Access, HEOR and Real-world Evidence, Certara Lee Stern, VP, Business Development, Certara Evidence & Access Ulrich Neumann, Sr. Director, Head US Access, Certara (ulrich.neumann@certara.com) --- Send in a voice message: https://anchor.fm/market-access/message ..read more

We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice. In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry.  Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Acc ..read more

In this episode, we're dissecting the US Administrations initiative to overhaul Medicare Part B drug reimbursement, incorporating international reference pricing. Experts on call Ulrich Neumann, Sr. Director, US Access ulrich.neumann@certara.com Additional notes: - We referenced the Implications of Pricing on Innovation which is thoroughly discussed in this article by USC's Darius Lakdawalla Lakdawalla, Darius N. 2018. "Economics of the Pharmaceutical Industry." Journal of Economic Literature, 56 (2): 397-449. DOI: 10.1257/jel.20161327 --- Send in a voice message: https://anchor.fm/market-acce ..read more